Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC) and Progyny (PGNY)

Tipranks - Sat Feb 28, 4:04AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOCResearch Report) and Progyny (PGNYResearch Report).

Claim 50% Off TipRanks Premium

Teladoc (TDOC)

In a report released today, Scott Schoenhaus from KeyBanc maintained a Hold rating on Teladoc. The company’s shares closed last Thursday at $5.35.

According to TipRanks.com, Schoenhaus ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.4% and a 27.5% success rate. Schoenhaus covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Elanco Animal Health, and Veeva Systems. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $7.27 average price target, which is a 52.7% upside from current levels. In a report issued on February 18, BTIG also maintained a Hold rating on the stock.

See the top stocks recommended by analysts >>

Progyny (PGNY)

Barclays analyst Peter Warendorf maintained a Buy rating on Progyny today and set a price target of $29.00. The company’s shares closed last Thursday at $22.25.

According to TipRanks.com, Warendorf is a 1-star analyst with an average return of -10.5% and a 33.3% success rate. Warendorf covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Healthequity, and Talkspace. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Progyny with a $29.65 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.